Unveiling Five Major Investments and Collaborations in the Constrained Peptide Drugs Market
As the demand for innovative therapeutics continues to rise, researchers and pharmaceutical companies increasingly focus on constrained peptides that are highly potent molecules with enhanced stability and specificity.
As per the BIS Research report, the global constrained peptide drugs market revenue is expected to generate $0.06 billion in 2024 and reach $17.38 billion by 2040, with a CAGR of 38.94% from 2025 to 2040.
Find more details on this report in this FREE sample.
The investments and collaborations represent significant milestones, bringing together cutting-edge technologies, scientific expertise, and strategic partnerships to drive breakthroughs in the constrained peptide drugs market.
This blog will unveil the major collaborations, investments, and recent developments held in the field of constrained peptide drugs and their transformative potential in therapeutics and drug discovery.
1. UBS Group AG Increases Stake in Protagonist Therapeutics
UBS Group AG has made a remarkable move by significantly increasing its stake in Protagonist Therapeutics Inc. in June 2023, demonstrating confidence in the company’s potential. As per the recent 13F filing with the Securities and Exchange Commission, UBS Group AG currently holds approximately 0.46% of Protagonist Therapeutics, with a substantial value of $2.46 million. With Protagonist Therapeutics shining in the critical sector, UBS Group AG appears well-positioned to achieve substantial returns from this investment.
2. Ono Pharma and PeptiDream Join Forces for Constrained Peptide Drug Discovery
Ono Pharma and PeptiDream, two Japanese drug manufacturers, formed a collaborative partnership for drug discovery in March 2023. The collaboration aims to identify and develop innovative macrocyclic constrained peptide drugs targeting multiple specific interests of Ono. PeptiDream would leverage its proprietary Peptide Discovery Platform System (PDPS) technology to identify and optimize potential drug candidates.
3. Mytide Therapeutics Secures $7 Million for Peptide Manufacturing Using Machine Learning
Mytide Therapeutics, a company utilizing predictive analytics and machine learning to revolutionize peptide manufacturing, secured $7 million in Series A funding in March 2022. The round was led by Alloy Therapeutics, with participation from Uncommon Denominator and the Mytide founding team.
This investment would enable Mytide to expand its AI-enabled Gen2 platform, facilitating cost-effective, scalable, and decentralized manufacturing for various therapeutic discovery and personal peptide vaccine applications.
4. Polyphor and EnBiotix Signed a Merger Agreement Announcing the Sale of Inhaled Murepavadin to EnBiotix
Polyphor and EnBiotix entered into a merger agreement in September 2021, where EnBiotix acquired Polyphor’s Inhaled Murepavadin for a valuation of $10 million. In exchange, Polyphor received 2,599,655 common shares of EnBiotix, representing a fully diluted stake of 15.4%.
Prior to the completion of the merger, EnBiotix aims to finalize a financing round, with current Polyphor shareholders expected to control approximately 23 to 26% of the combined entity listed on the SIX Swiss Exchange. The merger created a late-stage clinical development company to focus on cystic fibrosis and strategically emphasize rare diseases and oncology.
5. Protagonist Therapeutics Resolves Collaboration Agreement Dispute with Zealand Pharma
Protagonist Therapeutics, Inc. has successfully resolved its Collaboration Agreement dispute with Zealand Pharma. The agreement, which concludes the arbitration proceedings initiated by Protagonist in 2020, entails a 50% reduction in future development and sales milestone payments, excluding $2.5 million in near-term milestones, as well as royalties for the product candidate rusfertide. These milestone and royalty payments are applied to sales and milestones achieved by the Protagonist, any future licensee, or partner of rusfertide.
Conclusion
According to Akash Mhaskar, Principal Analyst, BIS Research, “The global constrained peptide drugs market is strongly driven by the rising incidence of target diseases such as cancers, rare diseases, and autoimmune disorders, as well as the increasing research for finding the new targets or moiety for the diseases.”
The global market for constrained peptide drugs has experienced consistent expansion due to the increasing influx of new participants and investments in the development of such drugs. Consequently, there is a rising demand for active pharmaceutical ingredients, peptide platforms, and software solutions essential for the manufacturing process of these innovative drugs.
Interested to know more about the developing technologies in your industry vertical? Get the latest market studies and insights from BIS Research. Connect with us at hello@bisresearch.com to learn and understand more.
